Abstract 47P
Background
Studies have shown disparities in management of older patients with breast cancer, resulting in undertreatment. Older patients with co-morbidities pose a challenge for cancer care providers who must balance the risk of death due to toxicity from treatment versus the benefit of standard multimodality treatment. The aim of the study was to evaluate whether the sequencing of chemotherapy and surgery impact the ability to deliver both modalities of treatment.
Methods
A retrospective analysis of prospective data was evaluated between 2018 and 2022. We included patients >60 years of age with chronic comorbidities, with a clinical stage T1c-3 and N0-3, HER2-positive or triple-negative invasive breast cancer treated with chemotherapy alone, surgery alone, or both surgery and chemotherapy. Kaplan-Meier curves were plotted to compare the survival outcomes. Statistical analysis was done using SPSS v25.
Results
A total of 821 patients met the inclusion criteria, of whom 85.9% (N=705) underwent surgery as the initial treatment. Among patients who received chemotherapy first (N=116), 73.3% (N=85) were able to complete subsequent surgery. Factors associated with completion surgery after chemotherapy were younger age and clinical node-negative status. Among patients treated with surgery first, only 36.3% (N=256) received adjuvant chemotherapy. Among patients who received both modalities of treatment (N=341), women with more advanced stage tumors and those diagnosed in recent years were more likely to receive neoadjuvant chemotherapy. With a median follow-up of 19.3 months, cN0 patients who underwent both surgery and chemotherapy had significantly better overall survival compared to patients who received single modality of treatment.
Conclusions
In older, triple-negative or HER2-positive breast cancer patients with comorbidities, receipt of chemotherapy and surgery was associated with improved survival. Neoadjuvant chemotherapy group were twice as likely to receive both modalities of treatment than those undergoing surgery first. A multidisciplinary approach to evaluate geriatric patients with comorbidities is essential to deliver appropriate treatment and improve outcomes in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract